GSK plc

GSK plc Intangible Assets

The Intangible Assets of GSK plc (GSK.L) as of Nov 8, 2026 is 15.52 B GBP. In the previous year, Intangible Assets was 14.77 B GBP — a change of 5.06% (higher).

Intangible Assets

15.52 BGBP

YoY

5.06%

Last updated:

Intangible Assets of GSK plc is 2024 15.52 B GBP. Intangible Assets of GSK plc was 2023 14.77 B GBP. It decreases by 5.06% higher compared to the previous year.

The GSK plc Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2017
17.56 B GBP
Jan 1, 2018
17.20 B GBP
Jan 1, 2019
30.96 B GBP
Jan 1, 2020
29.82 B GBP
Jan 1, 2021
30.08 B GBP
Jan 1, 2022
14.32 B GBP
Jan 1, 2023
14.77 B GBP
Jan 1, 2024
15.52 B GBP
The GSK plc Intangible Assets history
YEARIntangible AssetsYoY
15.52 BGBP+5.06%
14.77 BGBP+3.14%
14.32 BGBP-52.40%
30.08 BGBP+0.86%
29.82 BGBP-3.65%
30.96 BGBP+79.95%
17.20 BGBP-2.05%
17.56 BGBP-6.47%
18.78 BGBP+12.62%
16.67 BGBP+100.38%
8.32 BGBP—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GSK plc Stock analysis

What does GSK plc do? GSK plc generates revenue through its Pharmaceuticals and Vaccines segments, which focus on developing and selling prescription medicines and vaccines. The Pharmaceuticals segment offers products in Respiratory, HIV, Specialty, and Classic and Established categories, targeting acute and chronic diseases. The Vaccines segment provides over 40 vaccines for pediatric, adolescent, adult, and older populations, including travel vaccines. Customers include healthcare providers, hospitals, and consumers purchasing over-the-counter products. GSK's brand portfolio spans prescription medicines like those for Respiratory and HIV, alongside vaccines such as those for pediatric and adult health. The company's research focuses on six therapeutic areas: Respiratory diseases, HIV/infectious diseases, Vaccines, Immuno-inflammation, Oncology, and Rare diseases. This research drives product development for both segments, ensuring a steady pipeline of medicines and vaccines. The company's products are distributed globally, with the Pharmaceuticals business targeting healthcare professionals and the Vaccines business serving public health programs and individual consumers. GSK's strategy emphasizes innovation in key therapeutic areas to address unmet medical needs, leveraging its extensive research and development capabilities to maintain market leadership. GSK plc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GSK plc stock

Intangible Assets of GSK plc is 15.52 B GBP in 2024.

Intangible Assets of GSK plc changed from 14.77 B GBP to 15.52 B GBP, representing a 5.06% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets GSK plc since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's GBP is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's GSK plc historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — GSK plc

All Key Metrics — GSK plc